Roche has received U.S. FDA clearance for its Elecsys Phospho-Tau (217P) Plasma blood test, developed in collaboration with Eli Lilly, to help assess amyloid pathology associated with Alzheimer's disease. The assay is the first FDA-cleared single-biomarker blood test that can support both rule-in and rule-out assessment using the same validated clinical cutoffs in primary care and specialty settings. It is intended for adults aged 55 and older experiencing signs or symptoms of cognitive decline.
The test measures phosphorylated tau 217 (pTau217), a blood-based biomarker associated with amyloid pathology in the brain. Results classify patients into positive, intermediate or negative categories based on their likelihood of having amyloid pathology. This provides clinicians with a relatively simple blood test that can help determine which patients may require further Alzheimer's evaluation and which may be less likely to benefit from additional invasive or expensive testing.
Traditionally, confirming amyloid pathology has relied heavily on positron emission tomography (PET) imaging or analysis of cerebrospinal fluid collected through a lumbar puncture. These approaches can be expensive, invasive or difficult to access, particularly outside specialist centers. By introducing blood-based testing into primary care, Roche aims to enable earlier triage of patients with cognitive symptoms and potentially accelerate referrals for specialist evaluation, confirmatory testing and treatment.
A significant advantage is the test's ability to run on Roche's existing network of more than 4,500 cobas immunoassay analyzers across U.S. laboratories. This installed infrastructure could allow the assay to scale quickly without requiring healthcare organizations to purchase specialized new testing equipment, potentially making Alzheimer's biomarker testing more broadly accessible across different care settings.
The clearance comes as blood-based biomarkers increasingly reshape Alzheimer's diagnostics, particularly following the arrival of disease-modifying therapies that make earlier and more accurate identification of eligible patients increasingly important. The test also strengthens Roche and Lilly's broader strategies in Alzheimer's disease, connecting diagnostics with growing pipelines of therapies targeting the biological mechanisms underlying disease progression.
Click here to read the original news story.
